Evidence using cancer cell lines has indicated that KRAS antisense oligodeoxynucleotide inhibits KRAS expression, tumor growth, and tumor invasiveness [44, 45], and that the oligodeoxynucleotide can also suppress peritoneal dissemination of cancer cells in vivo [45, 46]. This evidence concerns the gene KRAS and neoplasm.